Novonesis AS (Novonesis AS) Total Liabilities : $2,054 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Novonesis AS Total Liabilities?

Novonesis AS's Total Liabilities for the quarter that ended in Dec. 2023 was $2,054 Mil.

Novonesis AS's quarterly Total Liabilities declined from Jun. 2023 ($2,099.71 Mil) to Sep. 2023 ($1,953.15 Mil) but then increased from Sep. 2023 ($1,953.15 Mil) to Dec. 2023 ($2,054.19 Mil).

Novonesis AS's annual Total Liabilities increased from Dec. 2021 ($1,908.68 Mil) to Dec. 2022 ($1,958.59 Mil) and increased from Dec. 2022 ($1,958.59 Mil) to Dec. 2023 ($2,054.19 Mil).

Novonesis AS Total Liabilities Historical Data

The historical data trend for Novonesis AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis AS Total Liabilities Chart

Novonesis AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,332.31

1,515.19

1,908.68

1,958.59

2,054.19

Novonesis AS Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															1,958.59	2,157.30	2,099.71	1,953.15	2,054.19

Novonesis AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Novonesis AS's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1062.504	+	(667.174	+	324.515
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2,054

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	4153.889	-	2099.696
	=	2,054

Novonesis AS's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1062.504	+	(667.174	+	324.515
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2,054

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	4153.889	-	2099.696
	=	2,054

Novonesis AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of Novonesis AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis AS (Novonesis AS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis AS (OTCPK:NVZMF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NZYM:Mexico NZYMBc:UK 0Q4U:UK NZYM B:Denmark NZM2:Germany

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novozymes is the world leader in industrial enzymes. In recent years, the company has expanded into micro-organisms, primarily for agricultural markets. The firm supplies five major industry groups: household care, food and beverages, bioenergy, agriculture and feed, and technical and pharma. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark.

Novonesis AS (Novonesis AS) Headlines

From GuruFocus

Novozymes A/S's Dividend Analysis

By GuruFocus Research • 10-19-2023

Not Just Yogurt Anymore

By PRNewswire • 10-26-2023

Novozymes Named EPA Safer Choice Partner of the Year for Third Year in a Row

By PRNewswire • 10-03-2023

2 Holdings to Reduce Based on Analyst Recommendations

By Alberto Abaterusso Alberto Abaterusso • 11-06-2019